Coya Therapeutics (COYA) announced that founder Howard Berman has stepped down as Executive Chairman and as a member of the Board, and that Mark Pavao has been appointed to the Board as an independent director. Berman became Executive Chairman in November 2024 as part of a planned CEO transition that established Arun Swaminathan, as the Company’s CEO. Dr. Berman’s departure from the Executive Chairman role was a contemplated next step in that process. Coya is also proud to announce that Mark H. Pavao is joining its Board, to fill the Board seat resulting from Dr. Berman’s departure. Pavao has held senior leadership roles at Biotech Value Advisors, LLC, R-Pharm US and Bristol-Myers Squibb.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- 3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
- Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating
- Coya publishes study showing reduction in regulatory T cell function in FTD
- Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD